About Bikam Pharmaceuticals
Bikam Pharmaceuticals is a company based in Cambridge (United States) founded in 2007 was acquired by Shire in July 2014. Bikam Pharmaceuticals has raised $11 million across 2 funding rounds from investors including Takeda Pharmaceuticals, CHL Medical Partners and Healthcare Ventures. Bikam Pharmaceuticals operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11 M (USD)
in 2 rounds
-
Latest Funding Round
$11 M (USD), Series A
Nov 02, 2007
-
Investors
Takeda Pharmaceuticals
& 3 more
-
Employee Count
Not available
-
Acquired by
Shire
(Jul 09, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Bikam Pharmaceuticals
Bikam Pharmaceuticals has successfully raised a total of $11M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bikam Pharmaceuticals
Bikam Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, CHL Medical Partners and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage healthcare services investments are facilitated by CHL.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Bikam Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bikam Pharmaceuticals
Investment portfolio details for Bikam Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bikam Pharmaceuticals
Detailed financials for Bikam Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bikam Pharmaceuticals Comparisons
Peer comparison for Bikam Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bikam Pharmaceuticals
Bikam Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Bikam Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bikam Pharmaceuticals
Complete news archive for Bikam Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bikam Pharmaceuticals
Bikam Pharmaceuticals was founded in 2007.
Bikam Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bikam Pharmaceuticals is a funded company, having raised a total of $11M across 2 funding rounds to date.
Bikam Pharmaceuticals was founded in 2007 in Cambridge, United States, within the biotechnology sector. Focus was placed on developing small molecule therapeutics targeting degenerative eye diseases. A lead compound, functioning as a pharmacological chaperone, was examined for preserving photoreceptor cell function in autosomal dominant retinitis pigmentosa. Operations centered on preclinical investigations. In July 2014, acquisition by Shire occurred for 2.5 million upfront, plus potential milestones up to 92 million.
Bikam Pharmaceuticals's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Bikam Pharmaceuticals has 4 investors. Key investors include Takeda Pharmaceuticals, CHL Medical Partners, Healthcare Ventures, and F-Prime Capital.